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Glucagon-like peptide-1(GLP-1) is a growth factor that has neuroprotective and anti-inflammatory properties. 
The protease resistant GLP-1 analogue liraglutide has been shown to be neuroprotective in previous studies 
in animal models of Alzheimer’s disease or Parkinson’s disease. Status epilepticus (SE) is a complex 
disorder, involving many underlying pathological processes, including excitotoxic and chronic inflammatory 
events. The present pilot study aims to investigate whether liraglutide alleviates the chronic inflammation 
response and mitochondrial stress induced by SE in the lithium-pilocarpine animal model. We found that 
treatment with 25nmol/ kg. i.p. once-daily after the induction of SE for 7 days reduced chronic inflammation 
as shown by reduced numbers of activated microglia and astrocytes, and reduced levels of TNF-a and IL-1ß 
in the hippocampus. The mitochondrial stress marker BAX was reduced and the survival factor Bcl-2 was 
enhanced by liraglutide. Blood glucose levels were not affected by liraglutide. We show for the first time that 
liraglutide can reduce the chronic inflammation and mitochondrial stress induced by SE, and the results 
suggest that GLP-1 receptor agonists such as liraglutide have restorative and protective effects in the brain 
after SE and could serve as a potential treatment. 
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Status epilepticus (SE) is a neurological condition that leads to substantial morbidity and mortality [1, 2]. On 
average, about 1/3-1/2 SE patients will get worse, and about 2/5 refractory epilepsy patients will die [3-5]. 
Surviving patients may suffer from cognitive disorders or neuronal impairments [6-8]. At present, 
benzodiazepines such as lorazepam and diazepam are widely applied as first-line treatments for SE [9]. 
Although injections of diazepam (10mg/kg) after the first seizure can effectively stop seizures and reduce 
mortality, it fails to impact on the resulting neurodegeneration [10, 11]. The currently available antiepileptic 
drugs can only alleviate symptoms of seizure, but not reduce the neurodegenerative processes induced by 
SE. 
Chronic inflammation of the brain also plays a crucial role in epileptogenesis. Inflammation of the 
hippocampus involves activated glial cells and the release of specific inflammatory cytokines [12, 13]. 
Activated microglia and astrocytes secrete pro-inflammatory cytokines such as interleukin 1β (IL-1β), tumour 
necrosis factor-α (TNF-α) and chemoattractant (MCP1) which can decrease seizure threshold [13-16]. In 
addition, peripheral immune cells including leukocytes, monocytes/ macrophages and granulocytes infiltrate 
the CNS after SE which contribute to the chronic epilepsy [17-19]. In the SE brain, astrocytic glutamate 
release leads to excessive accumulation in extracellular spaces [20-22]. Increased levels of glutamate will 
increase neuronal activity and enhance excitotoxicity by production of ROS/RNS [23-25]. Therefore, 
anti-inflammatory agents or antioxidants may be a promising strategy to reduce neuronal damage after SE 
[4, 15, 26].  
Liraglutide, a Glucagon-like peptide-1 (GLP-1) analogue, has been developed clinically for the treatment of 
type 2 diabetes mellitus (T2DM). The drug has a good safety profile with minimal adverse reaction [27, 28]. 
GLP-1 receptors (GLP-1R) are widely expressed in the brain on neurones, cell bodies and dendrites in the 
brain [29-31]. The GLP-1 analogue liraglutide can cross the blood-brain barrier (BBB) and activate GLP-1Rs 
[32, 33]. Liraglutide has shown neuroprotective effects in a range of animal models of neurodegenerative 
disorders, such as Alzheimer’s disease [33-35], Parkinson’s disease [36, 37], traumatic brain injury [38, 39], 
motor neurone disease/ ALS [40], or stroke [41, 42]. Furthermore, liraglutide has anti-inflammatory 
properties in models of chronic inflammation of the brain [33, 35, 43, 44]. A pilot clinical trial has shown 
protective effects in patients with Alzheimer’s disease [45], and another pilot study has shown improvements 
in cognitive performance and in MRI brain scans of people with mood disorders [46, 47]. In addition, the 
GLP-1 receptor agonist exendin-4 has shown good protective effects in a pilot study in Parkinson’s patients 
[48, 49]. A recently published phase II placebo- controlled double blind trial confirmed the initial results and 
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showed that exendin-4 stopped disease progression [50]. This proof of concept demonstrates that the 
approach of activating GLP-1 receptors as a neuroprotective treatment is valid and translates into the clinic. 
Therefore, liraglutide or other GLP-1 analogues have the potential to alleviate the pathological processes 
found in SE. We therefore tested liraglutide in the pilocarpine model of SE [51] at a dose that previously 
showed neuroprotective effects in the CNS [33]. We show for the first time that liraglutide has clear 
neuroprotective properties in this animal model. 
 
 
Materials and methods 
 
Animals  
Male Sprague-Dawley (SD) rats weight 200-250 g were used. All animals were provided by the Beijing Vital 
River Laboratory Animal Technology. And they were housed under controlled temperature (22±3℃), 
humidity (50-55%) and 12-h light/dark cycles with free access to food and water ad libitum. The work was 
licenced by the ethics committee of Shanxi province. All experimental procedures were conducted in 
accordance with the National Institutes of Health(NIH) guideline (National Institutes of Health Publications, 
No. 80-23, revised 1978). 
 
Liraglutide 
Liraglutide (Peptide Purity: 95.77%) was obtained from Chinapeptides Ltd (Shanghai, China). The purity of 
the peptide was confirmed by reversed-phase HPLC and characterised using matrix assisted laser 
desorption/ionisation time of flight (MALDI-TOF) mass spectrometry.  
 
Induction of SE  
The experimental rats were injected with lithium chloride (127 mg/kg, ip., Sigma-Aldrich, USA) 20 hours 
before atropine sulfate (1mg/kg, i.p., Tianjin Jinyao, China) which reduced the peripheral cholinergic effects 
of pilocarpine. Then, 30 minutes later, pilocarpine hydrochloride (30mg/kg, i.p., MedChem Express, USA) 
was administered. Each animal’s behaviour was evaluated according to Racine’s scale [52], and only those 
rats that exhibited ongoing convulsive seizures (level 4-5) for 30 min without recovery between seizures 
would be used as SE model. Diazepam (10mg/kg, i.p., Tianjin Jinyao, China) was used to treat the animals 
to terminate the convulsive seizures one hour after onset of SE. Based on the high mortality of 
pilocarpine-induced SE model, we would add animals to guarantee the numbers of each group. 
 
Experimental design 
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The 54 rats were divided into three groups: (I) saline treated control group (n=6); (II) pilocarpine treated 
group (n=24); (III) pilocarpine+liraglutide group (n=24). The pilocarpine group and pilocarpine+liraglutide 
group were divided into four subgroups (n=6) according to the different time points (12h, 1days, 3days, 
7days) after termination of SE. Following the termination, liraglutide (25 nmol/kg, ip.) was administered 
immediately once -daily in the pilocarpine+liraglutide group, while the pilocarpine group rats were treated 
with 0.9% NaCl saline instead. The dose of liraglutide was based on the studies showing beneficial effects in 
AD or PD [35, 53, 54]. 
 
Glucose measurements 
Blood samples from the tail vein were used for the glucose test. Blood glucose levels were tested before 
sacrifice at different time points (12 h, 1d, 3d, 7d after termination of SE) by a Sannuo blood glucose meter 
(Sinocare Inc. China). Repeated measurements were taken three times to reduce error and the average 
was taken as the blood glucose level. 
  
Western blot 
Three rats in each subgroup were sacrificed. Rats were anesthetized with 5% chloral hydrate (5ml/kg, ip.,). 
After cardiac perfusion with cold 0.9% NaCl, the brain was dissected on ice and hippocampi were removed. 
Hippocampus tissue was homogenised in ice cold RIPA buffer (Beyotime Institute of Biotechnology, China) 
added phenyl-methylsulfonyl fluoride (PMSF) and centrifuged 12000rpm/min (=3200g) for 10min at 4 ℃. 
Then, the supernatant was taken for detection of protein concentration by BCA Protein Assay Kit (Boster 
Institute of Biotechnology, China). After supernatant was mixed with loading buffer and boiled for 10 min, 
every sample that contained 20 ug protein was separated by 12% sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDA-PAGE) and then transferred to polyvinylidene difluoride (PVDF) membranes. Next, 
the membranes were blocked with 5% non-fat milk in 4℃ for one night to prevent nonspecific binding. 
Primary antibodies incubated overnight at 4℃ with rabbit anti-rat Bcl-2 (1:1000, bioworld technology, USA), 
rabbit anti-rat Bax (1:1000, Bioworld technology, USA), rabbit anti-rat IL-1β (1:1000, bioworld technology, 
USA), rabbit anti-rat TNF-α (1:1000, Abcam, UK) and rabbit anti-rat β-actin (1:3000, Bioworld, USA) diluted 
in PBS. After washing three times (10 min per wash) in TBST, membranes were incubated in goat anti-rabbit 
IgG with horseradish peroxidise conjugate (1:3000, Boster Institute of Biotechnology, China) for 2 hours and 
then washed three times in TBST. The protein bands were detected by ECL-enhanced chemiluminescence 
(Boster Institute of Biotechnology, China) and analysed by Image Lab 3.0 System.  
 
Immunohistochemistry 
After anesthetized with 5% chloral hydrate (5ml/kg, ip.,), the rats (n=3) were perfused with ice-cold 0.9% 
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saline followed by 4% paraformaldehyde (PFA). Then brains were obtained and postfixed in 4% PFA for 24 
hours at 4℃. After treatment with alcohol and xylene by a Leica TP1020 histology system, brains were 
embedded in paraffin and 5µm sections were cut on a Leica (Germany) microtome. The brain sections were 
incubated with 3% hydrogen peroxide (H2O2) for 10 min at room temperature (RT). Then, sections were 
treated with primary antibodies including rabbit anti-rat Bcl-2 (1:50, Bioworld technology, USA), rabbit 
anti-rat Bax (1:50, bioworld technology, USA), rabbit anti-rat IBA1 (1:100, Abcam, UK), rabbit anti-rat GFAP 
(1:100, Abcam, UK) and rabbit anti-rat TNF-α (1:1000, Abcam, UK) overnight at 4℃, then with goat 
anti-rabbit IgG (1:500, ZSGB-BIO) and incubated at 37℃ for 1 hour. The immunoreactivity was visualized 
with DAB (Boster Institute of Biotechnology, China) colour reaction. The CA1 region of the hippocampus was 
visualized with an Olympus BX51 (Olympus, Japan) microscope. For the analysis, stereological rules were 
applied. Three sections per brain were used for histology and two images were chosen randomly from each 
section (right and left hippocampus) to count the number of positive cells. The values obtained by the six 
analyzed images from one brain tissue were averaged before to enter the statistical analysis. The surface 
area analysed per disector was 1.10mm2. Image-Pro Plus 6.0 (Media Cybernetics, Silver Spring, USA) was 
applied for automated cell count. Thresholds for object size and intensity of the stain used were set to count 
the cells following the instructions of the manufacturer. The mean value of the positive cell numbers from 
images of each rat was used for statistical analysis.	
 
Statistical analysis 
All data were expressed as mean ± standard error (SEM). Statistical analyse software PRISM 5.0 
(GraphPad software, USA) was used for analysis. Data were analysed by one-way or two-way analysis of 






Measurements of plasma glucose levels  
A repeated measure two-way ANOVA did not find a difference between blood glucose levels in the two 
groups. Neither time (P>0.05, F=1.24) nor drug treatment (P>0.05, F=1.35) was significantly different (see 
Fig. 1).  
 
Histological analysis: 
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Activation of microglia and astrocytes in the hippocampus 
When analysing activated microglia numbers (IBA-1 positive cells) in the hippocampus, a two-way ANOVA 
found a significant difference between drug treatment (P<0.0001, DF=3, F=280.3) and time (P<0.0001, 
DF=1, F=381). Interaction was significant (P<0.0001, DF=3, F=216). Post-hoc repeated measures Tukey 
post-hoc tests found differences between groups (see Fig. 2). When measuring activated astrocyte numbers 
(GFAP positive cells) in the hippocampus, a two-way ANOVA found a significant difference between drug 
treatment (P<0.0001, DF=3, F=39) and time (P<0.0001, DF=1, F=19.6). Interaction was significant (P<0.05, 
DF=3, F=4.0). Post-hoc repeated measures Tukey post-hoc tests found differences between groups (see 
Fig. 3). Treatment with Liraglutide was able to reduce the chronic inflammation response. 
 
Levels of mitochondrial signalling peptides Bcl-2 and BAX in the hippocampus 
When evaluating the levels of Bcl-2 positive cells, a two-way ANOVA found a significant difference between 
drug treatment (P<0.0001, DF=3, F=21.3) and time (P<0.005, DF=1, F=9.15). Interaction was not significant. 
Post-hoc repeated measures Tukey post-hoc tests found differences between groups (see Fig. 4). 
Liraglutide treatment enhanced the levels of the protective signalling peptide Bcl2. When evaluating the 
levels of BAX positive cells, a two-way ANOVA found a significant difference between drug treatment 
(P<0.0001, DF=3, F=18.3) and time (P<0.0001, DF=1, F=149.2). Interaction was significant (P<0.0001, 
DF=3, F=9.3). Post-hoc repeated measures Tukey post-hoc tests found differences between groups (see 
Fig. 5). Liraglutide treatment reduced the levels of the autophagy and apoptosis signalling peptide BAX in 
the hippocampus.  
 
Western blot analysis: 
Liraglutide reduces the levels of pro-inflammatory cytokines 
When analysing the levels of TNF-a in the brain, a one-way ANOVA found a significant difference between 
groups (P<0.0001, F=19.56, DF=80). Post-hoc repeated measures Tukey post-hoc tests found differences 
between groups (see Fig. 6a). When analysing the levels of IL-1ß in the brain, a one-way ANOVA found a 
significant difference between groups (P<0.605, F=4.24, DF=80). Post-hoc repeated measures Tukey 
post-hoc tests found differences between groups (see Fig. 6b).  
 
Liraglutide reduces mitochondrial stress 
When analysing the levels of Bcl-2 (B-cell lymphoma 2 peptide) in the brain, a one-way ANOVA found a 
significant difference between groups (P<0.0001, F=14.64, DF=80). Post-hoc repeated measures Tukey 
post-hoc tests found differences between groups (see Fig. 6c). When analysing the levels of BAX in the 
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brain, a one-way ANOVA found a significant difference between groups (P<0.0001, F=13.7, DF=80). 





Inducing SE in the rats by lithium chloride and pilocarpine treatment induced chronic inflammation in the 
brain as observed in the increased activation of microglia and astrocytes and the release of the 
pro-inflammatory cytokines TNF-a and IL-1ß. Furthermore, mitochondrial function is compromised as 
indicated by the reduced levels of Bcl-2 and the increased levels of BAX. Bcl-2 is a mitochondrial signal that 
is released when the membrane potential in the mitochondrial cristae is within physiological levels. Bcl-2 
blocks autophagy and apoptosis. BAX is released in the mitochondria when the voltage potential in 
mitochondria is reduced, a sign of dysfunction and damage. BAX can induce the elimination and autophagy 
of mitochondria, and can furthermore induce apoptosis [55, 56]. We and others have shown that activation 
of the GLP-1 receptor can reverse the mitochondrial stress signalling induced by toxins and increase Bcl-2 
levels and decrease BAX levels [57-60]. In our study using pilocarpine to induce SE, liraglutide was able to 
partially reverse the changes in Bcl-2 and BAX levels, indicating that mitochondrial activity was rescued. The 
chronic inflammation observed in this SE rat model was also much reduced by liraglutide treatment. The 
number of activated microglia and astrocytes was reduced, and the levels of TNF-a and IL-1ß in the brain 
were reduced.  
Previous studies found that microglia and astrocytes play a key role in the pathophysiology of epilepsy [61]. 
Activated microglia and astrocytes go through changes in morphology and functions. For example, 
uncontrolled activation of astrocytes and microglia is related to (BBB disruption and the release of 
pro-inflammatory cytokines as shown here. The astrocyte cell processes are associated with BBB function 
by releasing chemical signals to control BBB uptake [62]. Pro-inflammatory cytokines and glutamate 
released by astrocytes may affect BBB permeability in multiple ways. The dysfunction of BBB- induced brain 
extravasation of serum albumin can lead to glial activation, inflammation and synaptogenesis which 
increases excitability and promotes epileptogenesis [63-65]. In addition, interleukin-1ß released by 
astrocytes can damage BBB integrity during seizures [66]. The inflammation response to acute seizures 
leads to a rapid increase in inflammatory cytokine levels including IL-1β, TNF-α, IL-6 and prostaglandins 
released by microglia and astrocytes [13, 14, 26, 67]. Following the seizures, activated glial cells release 
high amounts of cytokines in the hippocampus which can be detected at 12 hours, 1 days, 3 days, 7 days 
later. Our experimental results also observed that the activation of microglia and astrocytes in the CA1 
region of hippocampus is persistent. This finding confirms previous studies [26, 68]. The release of 
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inflammatory cytokines plays a vital role in the development of epileptogenesis [13, 16]. IL-1β can increase 
the NMDA-mediated inward Ca2+ currents, which induce the release of glutamate and modulates synaptic 
activity [62, 69]. Increased TNF-α induces a rapid upregulation of AMPA receptor levels that lack the GluR2 
subunit which also enhances the membrane permeability of Ca2+. These changes promote neuronal 
excitability. In addition, the IL-1β and TNF-α released by glia increase BBB permeability. The inhibition of 
IL-1β or TNF-α has been shown to prevent epileptic activity [70, 71]. Activation of the IL-1 receptor/Toll-like 
receptor can decrease the threshold of seizures [13, 72, 73]. In addition, activated astrocytes also regulate 
extracellular potassium levels and neurotransmitter levels [13]. Therefore, the prevention or reduction of 
astrocyte activation is part of the therapeutic effect of liraglutide. Activated microglia can promote astrocytic 
activation, and activated astrocytes feed back to microglia by releasing pro-inflammatory cytokines [62]. 
Liraglutide decreased the expression of IL-1β and TNF-α in the hippocampus, which contributes to the 
neuroprotective effect of this drug. Our results confirm previous studies that demonstrated protective effects 
of liraglutide in the PTZ kindling -induced epilepsy model and the corneal kindling epilepsy model. 
Pre-treatment with liraglutide prevented the seizure severity, normalised behavioural activity, reduced 
oxidative stress, and normalised the levels of key neurotransmitters in the brain [74, 75]. In addition, 
liraglutide has shown neuroprotective effects in a range of preclinical studies of other neurodegenerative 
disorders [76], such as Alzheimer’s disease [33-35], Parkinson’s disease [36, 37], traumatic brain injury [38, 
39], motor neurone disease / ALS [40], or stroke [41, 42]. A pilot clinical trial has shown protective effects of 
liraglutide in patients with Alzheimer’s disease [45], and another pilot study showed clear improvements in 
cognitive function and in MRI brain scans of key brain areas [46, 47]. Importantly, exendin-4, a different 
GLP-1R agonist with good neuroprotective effects has been tested in Parkinson’s patients with good results 
[48, 49]. A phase II double-blind, placebo controlled trial that recently finished confirmed the results from the 
pilot study, demonstrating that the strategy of activating GLP-1 receptors in the brain is a viable strategy in 
treating neurodegenerative disorders [50]. Consequently, liraglutide is currently in a phase II test in 
Alzheimer’s patients (clinical trial identifier NCT01843075) and in a phase II trial in Parkinson’s patients 
(NCT02953665). 
 
In conclusion, our results demonstrate that liraglutide alleviates brain inflammation and mitigates 
mitochondrial apoptotic signalling in a pilocarpine induced SE rat model. This suggests that liraglutide may 
be effective in treating patients that have experienced SE. 
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Fig.1: Blood plasma glucose levels of the two groups over time. A two-way repeated measures ANOVA did 
not find a difference between groups or over time. N=6 per group. 
 
Fig. 2: Number of activated microglia in area CA1 of the hippocampus. A two-way ANOVA found an overall 
difference between drug treatment and time, and a Tukey repeated measures post-hoc test found 
differences between time points and drug treatments. ***=p<0.001; **=p<0.01; *=p<0.05. Shown are 
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representative micrographs. Scale bar =40µm. A= Pilo 12h; B= Pilo day1; C= Pilo day 3; D=Pilo day7; 
E=Pilo+Lira 12h; F=Pilo+Lira day1; G=Pilo+Lira day3; H=Pilo+Lira day7; I=untreated. N=6 sections per 
group. 
 
Fig. 3: Number of activated astrocytes in area CA1 of the hippocampus. A two-way ANOVA found an overall 
difference between drug treatment and time, and a Tukey repeated measures post-hoc test found 
differences between time points and drug treatments. ***=p<0.001; **=p<0.01; *=p<0.05. Shown are 
representative micrographs. Scale bar =40µm. A= Pilo 12h; B= Pilo day1; C= Pilo day 3; D=Pilo day7; 
E=Pilo+Lira 12h; F=Pilo+Lira day1; G=Pilo+Lira day3; H=Pilo+Lira day7; I=untreated. 
 
Fig. 4: Number of Bcl-2 positive cells in area CA1 of the hippocampus. A two-way ANOVA found an overall 
difference between drug treatment and time, and a Tukey repeated measures post-hoc test found 
differences between time points and drug treatments. ***=p<0.001; **=p<0.01; *=p<0.05. Shown are 
representative micrographs. Scale bar =40µm. A= Pilo 12h; B= Pilo day1; C= Pilo day 3; D=Pilo day7; 
E=Pilo+Lira 12h; F=Pilo+Lira day1; G=Pilo+Lira day3; H=Pilo+Lira day7; I=untreated. 
 
Fig. 5: Number of BAX positive cells in area CA1 of the hippocampus. A two-way ANOVA found an overall 
difference between drug treatment and time, and a Tukey repeated measures post-hoc test found 
differences between time points and drug treatments. ***=p<0.001; **=p<0.01; *=p<0.05. Shown are 
representative micrographs. Scale bar =40µm. A= Pilo 12h; B= Pilo day1; C= Pilo day 3; D=Pilo day7; 
E=Pilo+Lira 12h; F=Pilo+Lira day1; G=Pilo+Lira day3; H=Pilo+Lira day7; I=untreated. 
 
Fig. 6: Levels of key biomarkers in the brain. A one-way ANOVA found an overall difference between groups, 
and a Tukey repeated measures post-hoc test found differences between time points and drug treatments. 
***=p<0.001; **=p<0.01; *=p<0.05. Shown are sample blots. Each group n=3. 
